![juno therapeutics juno therapeutics](https://www.flad.com/content/images/juno-therapeutics-scientific-research_18.jpg)
When the engineered T cell engages the target protein on the cancer cell, it initiates a cell-killing response against the cancer cell. Juno's CAR T cell technology inserts a gene for a particular CAR into the T cell, enabling it to recognize cancer cells based on the expression of a specific protein located on the cell surface. Juno's chimeric antigen receptor (CAR) technology genetically engineers T cells to recognize and kill cancer cells. Fate retains exclusive rights to its intellectual property for all purposes outside of programmed CAR and TCR immunotherapies.Ībout Chimeric Antigen Receptor (CAR) Technology For each product developed by Juno that incorporates modulators identified through the collaboration, Fate is eligible to receive approximately $50 million in target selection fees and clinical, regulatory and commercial milestones, as well as low single-digit royalties on sales. Juno will fund all mutual collaboration activities for an exclusive four-year research term.
![juno therapeutics juno therapeutics](https://m.media-amazon.com/images/I/41d0cFVHt9L.jpg)
"This partnership exemplifies the extension of our small molecule programming platform to additional hematopoietic cell types, such as T cells, as we continue to build and advance our innovative pipeline of programmed hematopoietic cellular therapeutic candidates."įinancial terms of the agreement include an upfront payment to Fate of $5 million and the purchase by Juno of one million shares of Fate common stock at $8.00 per share. "We are excited to establish this strategic alliance with Juno, a company that shares our deep commitment to developing transformative cellular therapeutics for patients afflicted with life-threatening disorders," said Christian Weyer, M.D., M.A.S., President and Chief Executive Officer of Fate Therapeutics. Juno has the option to extend the exclusive research term for two years through an additional payment and continued funding of collaboration activities. Juno will be responsible for the development and commercialization of engineered T cell immunotherapies incorporating Fate's small molecule modulators. Through the four-year research and development collaboration, Fate will be responsible for screening and identifying small molecules that modulate the biological properties of engineered T cells. "Partnering with Fate Therapeutics, and accessing its strong science and leading platform for modulating the properties of immunological cells, enables interrogation of new avenues of T cell manipulation and provides an opportunity to enhance the therapeutic profile of our genetically-engineered T cell product candidates." "A deep understanding of T cell biology is the basis of Juno's approach to creating best-in-class cellular immunotherapies," said Hans Bishop, Chief Executive Officer of Juno Therapeutics. Properties and in vivo therapeutic potential of hematopoietic cells. The collaboration brings together Juno's industry-leading expertise in the development of chimeric antigen receptor (CAR) and T cell receptor (TCR) based cellular immunotherapies and Fate's innovative platform for programming the biological
#Juno therapeutics license#
(Nasdaq:FATE) announced today that they have executed a strategic research collaboration and license agreement to identify and utilize small molecules to modulate Juno's genetically-engineered T cell product candidates to improve their therapeutic potential for cancer patients. (Nasdaq:JUNO) and Fate Therapeutics, Inc. SEATTLE and SAN DIEGO, (GLOBE NEWSWIRE) - Juno Therapeutics, Inc. Juno Therapeutics and Fate Therapeutics Announce Strategic Research Collaboration to Improve the Therapeutic Profile of Engineered T Cell Immunotherapies 27.1 KB